Genentech's Vabysmo Slowly Chips Away at Competition in the Neovascular (Wet) AMD Market While Regeneron's Eylea Holds its Ground (For Now), According to New Spherix Report
/PRNewswire/ -- Since the FDA approval in January this year, ophthalmologists have been very optimistic about their intended use of Genentechs Vabysmo...
Susvimo Genentech Chrystal Ferguson Coherus Biosciences Genentech Susvimo Genentech Vabysmo Abbvie Regenxbio
Source: prnewswire.com